Obesity Clinical Trial
Official title:
Diet and Systemic Inflammation
People with chronic low-grade inflammation have a higher risk for certain diseases such as cardiovascular disease or type 2 diabetes. While it is known that obese people are more likely to show signs of low-grade inflammation than lean individuals, it is unclear what causes this inflammation. In the proposed study, the investigators will examine whether the sugar fructose, when consumed in a sweetened beverage, triggers low-grade inflammation in healthy men and women compared with other caloric sweeteners.
The objective of this proposal is to investigate whether fructose-sweetened beverages
trigger low-grade systemic inflammation in healthy men and women. Low-grade systemic
inflammation, specifically elevated plasma concentrations of C-reactive protein (CRP), is a
risk factor for cardiovascular disease (CVD). While it is known that obesity is associated
with inflammation, the causes of low-grade inflammation in humans are not well understood.
In a pilot study, the consumption of large amounts of fructose-, but not glucose- or
aspartame-sweetened beverages potently induced low-grade inflammation in healthy, lean,
young men and women in as little as 8 days. The investigators propose to extend these
findings by (a) enrolling a greater number of subjects, (b) enrolling obese as well as
non-obese subjects, and (c) including a beverage that is sweetened with high fructose corn
syrup (HFCS). HFCS is one of the primary sugars consumed in the United States, and a major
source of dietary fructose. Our primary specific aim is to assess whether the consumption of
fructose- or HFCS-sweetened beverages promotes systemic low-grade inflammation, as measured
by plasma concentrations of CRP and IL-6. The investigators hypothesize that plasma CRP and
IL-6 concentrations will be elevated after consumption of fructose-containing beverages
(fructose and HFCS) when compared to a glucose-sweetened beverage. Our secondary specific
aim is to assess whether the consumption of fructose- or HFCS-sweetened beverages lowers
plasma adiponectin concentrations. Specifically, the investigators hypothesize that total
and high molecular weight (HMW)-adiponectin concentrations in fasting plasma will be lower
after subjects have consumed the fructose- or HFCS-sweetened beverages, compared to a
glucose-sweetened beverage.
The investigators will recruit 12 overweight/obese (BMI between 25.0 and 40 kg/m2) and 12
normal weight (BMI between 20 and 24.9 kg/m2) men and women who are free of chronic
inflammatory or metabolic disease. In a double-blind, randomized cross-over design, each
subject will complete three 8-day standardized dietary periods that will differ only in the
type of sweetened beverage administered. Specifically, subjects will be asked to drink four
servings of a beverage each day that is sweetened with glucose, fructose, or HFCS (55%
fructose, 45% glucose). All solid food will be provided for each of the three 8-day diet
periods, and will be consumed ad libitum. Following each dietary period, the investigators
will collect fasting blood to measure markers of systemic inflammation and plasma
concentrations of total and HMW-adiponectin. We will also assess changes in adipose tissue
inflammation and intestinal permeability as potential mechanisms by which fructose-sweetened
beverages may trigger systemic inflammation. This study has the potential to identify a
dietary trigger of low-grade inflammation, a likely contributor to CVD and metabolic
diseases. The public health impact of this project might be considerable given that the
consumption of fructose in the population is pervasive, and is modifiable on an individual
as well as a population level.
;
Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator, Outcomes Assessor), Primary Purpose: Basic Science
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT04243317 -
Feasibility of a Sleep Improvement Intervention for Weight Loss and Its Maintenance in Sleep Impaired Obese Adults
|
N/A | |
Recruiting |
NCT04101669 -
EndoBarrier System Pivotal Trial(Rev E v2)
|
N/A | |
Terminated |
NCT03772886 -
Reducing Cesarean Delivery Rate in Obese Patients Using the Peanut Ball
|
N/A | |
Completed |
NCT03640442 -
Modified Ramped Position for Intubation of Obese Females.
|
N/A | |
Completed |
NCT04506996 -
Monday-Focused Tailored Rapid Interactive Mobile Messaging for Weight Management 2
|
N/A | |
Recruiting |
NCT06019832 -
Analysis of Stem and Non-Stem Tibial Component
|
N/A | |
Active, not recruiting |
NCT05891834 -
Study of INV-202 in Patients With Obesity and Metabolic Syndrome
|
Phase 2 | |
Active, not recruiting |
NCT05275959 -
Beijing (Peking)---Myopia and Obesity Comorbidity Intervention (BMOCI)
|
N/A | |
Recruiting |
NCT04575194 -
Study of the Cardiometabolic Effects of Obesity Pharmacotherapy
|
Phase 4 | |
Completed |
NCT04513769 -
Nutritious Eating With Soul at Rare Variety Cafe
|
N/A | |
Withdrawn |
NCT03042897 -
Exercise and Diet Intervention in Promoting Weight Loss in Obese Patients With Stage I Endometrial Cancer
|
N/A | |
Completed |
NCT03644524 -
Heat Therapy and Cardiometabolic Health in Obese Women
|
N/A | |
Recruiting |
NCT05917873 -
Metabolic Effects of Four-week Lactate-ketone Ester Supplementation
|
N/A | |
Active, not recruiting |
NCT04353258 -
Research Intervention to Support Healthy Eating and Exercise
|
N/A | |
Completed |
NCT04507867 -
Effect of a NSS to Reduce Complications in Patients With Covid-19 and Comorbidities in Stage III
|
N/A | |
Recruiting |
NCT03227575 -
Effects of Brisk Walking and Regular Intensity Exercise Interventions on Glycemic Control
|
N/A | |
Completed |
NCT01870947 -
Assisted Exercise in Obese Endometrial Cancer Patients
|
N/A | |
Recruiting |
NCT06007404 -
Understanding Metabolism and Inflammation Risks for Diabetes in Adolescents
|
||
Recruiting |
NCT05972564 -
The Effect of SGLT2 Inhibition on Adipose Inflammation and Endothelial Function
|
Phase 1/Phase 2 | |
Recruiting |
NCT05371496 -
Cardiac and Metabolic Effects of Semaglutide in Heart Failure With Preserved Ejection Fraction
|
Phase 2 |